Heron Therapeutics Inc (Heron) is engaged in the development of novel, patient-focused therapeutic products using its proprietary Biochronomer polymer-based drug delivery technology to address major unmet medical needs. It designs, develops and commercializes products for acute care and oncology patients. The company’s proprietary technology, Biochronomer, is a polymer-based proprietary drug delivery platform consisting of polymers designed to deliver therapeutic levels of short-acting pharmacological agents over days to weeks with a single administration.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Heron's R&D focuses on obtaining and maintaining international and domestic patents and other legal protections for its proprietary technology, inventions, and improvements. The company actively seeks patent protection in the U.S. and selected foreign countries for its product candidates in research and development programs, covering claims for composition of matter, medical uses, processes for preparation, and formulations. The company has filed a number of U.S. patent applications related to the composition of various polymers, specific products, product groups, and processing technology. In FY2025, the company spent US$12.4 million on its R&D activities, which as a percentage of revenue stood at 8%. As of December 2024, the company had a total of 33 issued patents in the US and an additional 107 issued (or registered) foreign patents, and had employed 7 people in R&D initiatives.